Bota Bio, a San Francisco CA-based and Hangzhou, China-based biotechnology company, raised $100M in Series B funding.
The round, which brought total funding to $145M, was led by Sequoia Capital China with participation from Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners and 5Y Capital.
The company intends to use the funds to expand global operations and build out its lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of its product pipeline in consumer goods, food, nutrition, and pharmaceutical products.
Led by Cheryl Cui, Ph.D., co-founder and CEO, Bota Bio is a global industrial biotechnology company focused on programming biological systems and scaling sustainable production of biomolecules. The company has developed and deployed a technology platform – known as the Bota Freeway – that integrates advanced digital tools with lab automation. Bota Bio has also expanded synthetic biology’s design-build-test-learn cycle to include downstream process development and select non-traditional microbial strains, accelerating the design and evolution of enzymes and cell-based factories.
The company previously announced its strategic investment led by BASF Venture Capital (BVC), the corporate venture arm of BASF Group, to bring sustainably produced ingredients to market.